SmartPA Criteria Proposal

Drug/Drug Class:	Targeted Immune Modulators, Interleukin (IL)-17A Antibody/IL-17 Receptor Antagonists PDL Edit
First Implementation Date:	January 22, 2004
Proposed Date:	September 15, 2022
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	☐ Existing Criteria ☒ Revision of Existing Criteria ☐ New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Interleukins (ILs) are pro-inflammatory cytokines that stimulate the recruitment and proliferation of other immune cells, leading to an increase in inflammation at the site of activity. The IL-17 pathway plays a major role in several autoimmune disorders including ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and spondyloarthritis. The monoclonal antibodies within this class lead to the reduction of proinflammatory cytokines associated with these disease states. Taltz® and Cosentyx® selectively bind to interleukin 17A (IL-17A) and inhibit its interaction with the IL-17 receptor while Siliq® binds to the IL-17 receptor and inhibits its interaction with IL-17 cytokines. These agents are commonly reserved for patients with moderate-to-severe cases after failure to control with first-line therapies.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:

Preferred Agents	Non-Preferred Agents
• Taltz®	• Cosentyx® • Siliq®

Type of Criteria:

☐ **Increased risk of ADE**	☒ **Preferred Drug List**
☒ **Appropriate Indications**	☐ **Clinical Edit**

Data Sources:

☐ **Only Administrative Databases**	☒ **Databases + Prescriber-Supplied**

Setting & Population

- Drug class for review: Targeted Immune Modulators, Interleukin (IL)-17 Antibody/IL-17 Receptor Antagonists
- Age range: All appropriate MO HealthNet participants aged 18 years or older unless otherwise indicated

Approval Criteria

- Documented compliance on current therapy **OR**
- Adequate therapeutic 6 month trial of tumor necrosis factor (TNF) inhibitor (trial defined as duration of therapy with class not agent) **AND**
- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
  - Documented trial period of preferred agent (6 months of therapy) **OR**
  - Documented ADE/ADR to preferred agent **OR**
- Documentation of appropriate diagnosis and participant age range for requested agent:

Generic	Brand	Indication
Ixekizumab	Taltz®	• Ankylosing spondylitis • Non-radiographic axial spondyloarthritis • Plaque psoriasis (aged 6 or older) • Psoriatic arthritis
Secukinumab	Cosentyx®	• Ankylosing spondylitis • **Enthesitis-related arthritis (aged 4 or older)** • Non-radiographic axial spondyloarthritis • Plaque psoriasis (aged 6 or older) • Psoriatic arthritis **(aged 2 or older)**
Brodalumab	Siliq®	• Plaque psoriasis

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:	☐	Progress Notes:	☐
MedWatch Form:	☐	Other:	☐

Disposition of Edit

Denial: Exception Code “0160” (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine Analysis: “Targeted Immune Modulators (Biologics – DMARDS [IL-6, TNF, IL-17A Antibody/IL-17 RA & IL-23/IL-12, JAK Inhibitors, CAPs agents, Select/Other Agents])”. UMKC-DIC; August 2022.
- Evidence-Based Medicine and Fiscal Analysis: “Targeted Immune Modulators: Interleukin (IL)-17, -12/23 and -23 Inhibitors– Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; June 2021.
- Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; December 2021.
- Siliq [package insert]. Bridgewater, NJ: Bausch Health US, LLC; April 2020.
- Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; May 2022.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.USPDI, Micromedex; 2022.